Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality
Yang Zhou, Shujing Xu, Nerea López-Carrobles, et al.
Acta Materia Medica (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 10

Showing 10 citing articles:

Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges
Shaoqing Du, Xueping Hu, Luis Menéndez‐Arias, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101053-101053
Closed Access | Times Cited: 14
Nucleoside antiviral agents with atypical structures and new targets
Hui Xu, B. Li, Kai Tang, et al.
Bioorganic & Medicinal Chemistry Letters (2025) Vol. 119, pp. 130110-130110
Closed Access
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)
Shuo Wang, Fareeda Ma, Kai Tang, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Insights into Virus-Host Interactions: Lessons from Caenorhabditis elegans-Orsay Virus Model
Xin Wu, Heng Liu, Yusong R. Guo
Current Medical Science (2025)
Closed Access
Rational Design of Methylene Blue–Raloxifene Conjugates for Efficient Breast Tumor Elimination Triggered by ERα Degradation
Yu Zhang, Qi-Ying Yu, Ziwei Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Discovery and mechanism verification of first-in-class hydrophobic tagging-based degraders of HBV core protein
Shujing Xu, Ya Wang, Dazhou Shi, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
Harnessing PROTACs to combat H5N1 influenza: A new frontier in viral destruction
Nobendu Mukerjee, Swastika Maitra, Dattatreya Mukherjee, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 9
Open Access | Times Cited: 1
The latest developments in the design and discovery of non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV
Junyi Li, Bing Ye, Shenghua Gao, et al.
Expert Opinion on Drug Discovery (2024), pp. 1-18
Closed Access | Times Cited: 1
Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy
Xinyang Shen, Yuan Ma, Hang Luo, et al.
Pharmaceutics (2024) Vol. 17, Iss. 1, pp. 40-40
Open Access | Times Cited: 1
Ligands and receptors in human cytomegalovirus entry: Current therapies and new directions
Min Zhang, Xiaochen Wang, Jianshe Li, et al.
Drug Discovery Today (2023) Vol. 29, Iss. 1, pp. 103833-103833
Closed Access | Times Cited: 1
Unveiling Innovative anti-influenza Agents Through Modern Medicinal Chemistry Approaches (2019–2023 updates)
Chuanfeng Liu, Lide Hu, Huinan Jia, et al.
Future Medicinal Chemistry (2023) Vol. 15, Iss. 21, pp. 1915-1917
Closed Access
Page 1

Scroll to top